HIGHLIGHTS
- who: Lisa Milchram et al. from the Center for Health and Bioresources, Competence Unit Molecular Diagnostics, AIT Austrian Institute of Department of Neurosurgery, Medical University of Vienna, Vienna, Austria have published the paper: Antibody Profiling and In Silico Functional Analysis of Differentially Reactive Antibody Signatures of Glioblastomas and Meningiomas, in the Journal: (JOURNAL)
SUMMARY
Glioblastomas are the most aggressive type of brain tumor with poor prognosis, with an incidence of 3.19-4.17 cases per 100,000 person-years. The formation of tumor-associated antibodies (TAAs)-more precisely, the induction of antibody . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.